Klotho Neurosciences, Inc. (KLTO) has officially signed a securities purchase agreement. According to the latest filings submitted to the U.S. Securities and Exchange Commission (SEC), the company plans to issue a total of 34.6 million shares of common stock.

This equity financing aims to provide funding support for the company's subsequent research and development as well as operational activities in the field of neuroscience. Market analysts point out that such financing activities typically reflect the company's confidence in the progress of its R&D pipeline and its need for capital for future business expansion. However, the issuance of new shares may also have a certain dilutive effect on existing shareholders' equity, with the specific impact depending on the final issuance terms and market subscription conditions.